Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

A team led by the University of Sydney has identified red blood cell rupture at dying endothelial sites as a primary driver of microvascular obstruction in COVID-19, bypassing the expected role of ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...

Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and ...